Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 3, 2008, Pages 146-153

  Nozue, Tsuyoshi ^a   Michishita, Ichiro ^a   Ito, Yasuki ^b   Hirano, Tsutomu ^c  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

^b DENKA COMPANY LIMITED   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Familial hypercholesterolemia; Remnant like particle cholesterol; Small dense low density lipoprotein cholesterol; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PYRROLE DERIVATIVE; QUINOLINE DERIVATIVE; REMNANT LIKE PARTICLE CHOLESTEROL; REMNANT-LIKE PARTICLE CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; BIOLOGICAL MODEL; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETICS; HETEROZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PYRROLES; QUINOLINES; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 48849094986     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E552     Document Type: Article

References (44)

1. Goldstein JL, Hobbs HH, and Brown MS: Familial hypercholesterolemia. In: The Metabolic Basis of Inherited Disease. 8th Ed, ed by Scriver CR, Beaudet AL, Sly WS, and Valle D, pp 2863-2913, McGraw-Hill, New York, 2001
2. Mabuchi H, Miyamoto S, Ueda K, Oota M, Takegoshi T, Wakasugi T, and Takeda R: Causes of death in patients with familial hypercholesterolemia. Atherosclerosis, 1986; 61:1-6
3. Hoeg JM: Homozygous familial hypercholesterolemia: a paradigm for phenotypic variation. Am J Cardiol, 1993; 72:11D-14D
4. Hokanson JE and Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk, 1996; 3:213-219
5. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR Jr., O'Grady HK, and Davis CE: Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med, 1993; 328:1220-1225
6. Campos E, Nakajima K, Tanaka A, and Havel RJ: Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. J Lipid Res, 1992; 33:369-380
7. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, and Havel RJ: Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta, 1993; 223:53-71
8. McNamara JR, Shah PK, Nakajima K, Cupples LA, Wilson PW, Ordovas JM, and Schaefer EJ: Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis, 2001; 154:229-236
9. Masuoka H, Kamei S, Ozaki M, Kawasaki A, Shintani U, Ito M, and Nakano T: Predictive value of remnant-like particle cholesterol as an indicator of coronary artery stenosis in patients with normal serum triglyceride levels. Intern Med, 2000; 39:540-546
10. Masuoka H, Kamei S, Wagayama H, Ozaki M, Kawasaki A, Tanaka T, Kitamura M, Katoh S, Shintani U, Misaki M, Sugawa M, Ito M, and Nakano T: Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J, 2000; 139:305-310
11. Watts GF: Postprandial lipaemia in familial hypercholesterolaemia: clinical and metabolic significance. Atherosclerosis, 2000; 148:426-428
12. Gardner CD, Fortmann SP, and Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA, 1996; 276:875-881
13. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, and Després JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation, 1997; 95:69-75
14. Koba S, Hirano T, Yoshino G, Sakai K, Sakaue T, Adachi M, and Katagiri T: Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes. Atherosclerosis, 2002; 160:249-256
15. Krauss RM and Burke DJ: Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res, 1982; 23:97-104
16. Hirano T, Ito Y, Saegusa H, and Yoshino G: A novel and simple method for quantification of small, dense LDL. J Lipid Res, 2003; 44:2193-2201
17. Hirano T, Ito Y, and Yoshino G: Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb, 2005; 12:67-72
18. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, Yamazaki J, and Yoshino G: Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol, 2004; 24:558-563
19. Kajinami K, Koizumi J, Ueda K, Miyamoto S, Takegoshi T, and Mabuchi H: Effects of NK-104, a new hydroxy-methylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol, 2000; 85:178-183
20. Wierzbicki AS, Lumb PJ, Semra YK, and Crook MA: High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. QJM, 1998; 91:291-294
21. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, and Dugi KA: Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis, 2004; 175:325-331
22. Mabuchi H, Ito S, Haba T. Ueda K, and Ueda R: Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles' tendon thickness, Atherosclerosis, 1977, 28:61-68
23. Yamada S, Inoue K, Marishita R, Ogihara T, Kubono K, Kubo N, Abe A, and Sakurabayashi I: A new Lp(a) assay that is unaffected by apo(a) size polymorphism. Clin Chim Acta 1999; 287:29-43
24. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, and Hennekens CH: A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction, JAMA, 1996; 276:882-888
25. Talmud PJ, Edwards KL, Turner CM, Newman B, Palmen JM, Humphries SE, and Austin MA: Linkage of the cholesteryl ester transfer protein (CETP) gene to LDL particle size: use of a novel tetranucleotide repeat within the CETP promoter. Circulation, 2000; 101:2461-2466
26. Chung BH, Segrest JP, and Franklin F: In vitro production of beta-very low density lipoproteins: and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin: cholester acyltransferase, cholesterylester transfer proteins and lipoprotein lipase. Atherosclerosis, 1998; 141:209-225
27. Carr MC, Ayyobi AF, Murdoch SJ, Deeb SS, and Brunzell JD: Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol, 2002; 22:667-673
28. Hogue JC, Lamarche B, Gaudet D, Lariviér M, Tremblay AJ, Bergeron J, Lemieux I, Després JP, Gagné C, and Couture P: Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. J Lipid Res, 2004; 45:1077-1083
29. Hugue JC, Lamarche B, Gaudet D, Tremblay AJ, Després JP, Gagné C, and Couture P: Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia, Atherosclerosis, 2006; 184:163-170
30. Nozue T, Michishita I, Ishibashi Y, Ito S, Iwaki T, Mizuguchi I, Miura M, Ito Y, and Hirano T: Small dense low-density lipoprotein cholesterol is a useful marker of metabolic syndrome in patients with coronary artery disease, J Atheroscler Thromb, 2007; 14:202-207
31. Tokuno A, Hirano T, Hayashi T, Mori Y, Yamamoto T, Nagashima M, Shiraishi Y, Ito Y, and Adachi M: The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes, J Atheroscler Thromb, 2007; 14:128-132
32. Guerin M, Egger R Soudant C, Le Goff W, van Tol A, Dupuis R, and Chapman MJ: Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol offlux, Atherosclerosis, 2002; l63:287-296
33. Lariviere M, Lamarone B, Pirro M, Hogue JC, Bergeron J, Gagne C, and Couture P: Effects of atorvastatin on electrophorotic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia Atherosclerosis, 2003; 167:97-104.
34. Hoogerbrugge N and Jansen H: Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia, Atherosclerosis, 1999; 146:167-174
35. Yoshino G, Hirano T, and Kazumi T: Treatment of small dense LDL J Atheroscler Thromb, 2002; 9:266-275
36. de Sauvage Nolting PR, Twickler MB, Dallinga-Thie GM, Buirma RJ, Hutten BA, and Kastelein JJ: Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia (ExPRESS) Study Group: Elevated remnant-like particles in heterozygous familial hypercholesterolemia and response to statin therapy. Circulation, 2002; 106:788-792
37. Twickler TB, Dallinga-Thie GM, de Valk HW, Schreuder PC, Jansen H, Cabezas MC, and Erkelens DW: High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia, Arterioscler thromb Vasc Biol, 2000; 20:2422-2427
38. Stein DT, Devaraj S, Balis D, Adams-Huet B, and Jialal I: Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia. Arterioscler Thromb Vasc Biol, 2001; 21:2026-2031
39. Horton JD, Shimano H, Hamilton RL, Brown MS, and Goldstein JL: Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest, 1999; 103:1067-1076
40. Bradley WA, Hwang SL, Karlin JB, Lin AH, Prasad SC, Gotto AM Jr, and Gianturco SH: Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins, J Biol Chem, 1984; 259:14728-14735
41. de Grooth GJ, Smilde TJ, Van Wissen S, Klerkx AH, Zwinderman AH, Fruchart JC, Kastelein JJ, Stalenhoef AF, and Kuivenhoven JA: The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia, Atherosclerosis, 2004; 173:261-267
42. Suehiro T, Ohguro T, Sumiyoshi R, Yasuoka N. Nakauchi Y, Kumon Y, and Hashimoto K: Relationship of low-density lipoprotein particle size to plasma lipoproteins, obesity, and insulin resistance in Japanese men. Diabetes Care, 1995; 18:333-338
43. Kazumi T, Kawaguchi A, Hozumi T, Nagao M. Iwahashi M, Hayakawa M. Ishihara K, and Yoshino G: Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis, 1999; 142:113-119
44. Iwai M, Yoshino G, Matsushita M, Morita M, Matsuba K, Kazumi T, and Baba S: Abnormal lipoprotein composition in normolipidemic diabetic patients. Diabetes Care, 1990; 13:792-796